Press Releases

12.09.2015

Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers

12.08.2015

BIOATLA ENTERS INTO STRATEGIC LICENSE AND OPTION AGREEMENT WITH PFIZER FOR A NEW CLASS OF ANTIBODY THERAPEUTICS

12.08.2015

Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program

12.08.2015

Pfizer Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for XALKORI® (crizotinib) for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer

12.08.2015

Pfizer Awards More Than $4 Million in Grants to Further Clinical Research in Advanced Breast Cancer for 2015

12.07.2015

Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII

11.30.2015

HEPTARES ENTERS STRATEGIC DRUG DISCOVERY COLLABORATION WITH PFIZER INC. FOCUSED ON GPCR TARGETS ACROSS MULTIPLE THERAPEUTIC AREAS

11.30.2015

Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

11.25.2015

Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA® (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain

11.24.2015

Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products

11.24.2015

Pfizer Receives European Approval to Expand Use of XALKORI® (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer

11.23.2015

Pfizer And Allergan To Combine